Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Review

A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer

verfasst von: Nahla E. El-Ashmawy, Rania M. Khalil

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

l-carnitine is an antioxidant and is found to be a protective agent against many diseases including cancer. This review illustrates the possible role of l-carnitine as an add-on therapy to breast cancer patients maintained on tamoxifen. The objectives of carnitine treatment are diverse: improving tamoxifen-related side effects, offering better cancer prognosis by reducing the risk of developing cancer recurrence or metastasis, and modulating the growth factors which may be, in part, a prospective illustration to overcome tamoxifen resistance. So, it could be recommended to supplement l-carnitine to breast cancer patients starting tamoxifen treatment.
Literatur
1.
Ahmad S. l-carnitine in dialysis patients. Semin Dialysis. 2001;14(3):209–17.
2.
Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol. 2008;294:R352–61.PubMed
3.
Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig. 2006;26(5):297–302.PubMed
4.
Al-Majed AA. Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007;100(3):145–50.PubMed
5.
Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol. 2009;15(11):1373–80.PubMedCentralPubMed
6.
Andreasen EB, Tranholm M, Wiinberg B, Markussen B, Kristensen AT. Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Vet Scand. 2012;54(1):3–30.PubMedCentralPubMed
7.
Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci USA. 2011;108:18879–86.PubMedCentralPubMed
8.
Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev. 2012;2012:609421–34.PubMedCentralPubMed
9.
Biolo G, Toigo G, Ciocchi B, Situlin R, Iscra F, Gullo A, et al. Metabolic response to injury and sepsis: changes in protein metabolism. Nutrition. 1997;13:52S–7S.PubMed
10.
Borghi-Silva A, Baldissera V, Sampaio LM, Pires-DiLorenzo VA, Jamami M, Demonte A, et al. l-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs. Braz J Med Biol Res. 2006;39(4):465–74.PubMed
11.
Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health. 2000;31(1):71–85.PubMed
12.
Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012;3(4):345–64.PubMedCentralPubMed
13.
Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signalling and inhibition in breast cancer. Curr Cancer Drug Ther. 2009;9:419–38.
14.
Campbell CI, Petrik JJ, Moorehead RA. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Mol Cancer. 2010;9:235–50.PubMedCentralPubMed
15.
Cao Y, Qu HJ, Li P, Wang CB, Wang LX, Han ZW. Single dose administration of l-carnitine improves antioxidant activities in healthy subjects. Tohoku J Exp Med. 2011;224(3):209–13.PubMed
16.
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006;17:1120–7.PubMed
17.
Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63(4):641–6.PubMed
18.
Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008;23:16–34.PubMed
19.
Chan AL, Leung HW, Wang SF. Multivitamin supplement use and risk of breast cancer: a meta-analysis. Ann Pharmacother. 2011;45(4):476–84.PubMed
20.
Chang B, Nishikawa M, Nishiguchi S, Inoue M. l-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer. 2005;113:719–29.PubMed
21.
Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea. 2008;27:574–9.PubMed
22.
Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. l-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004;1033:168–76.PubMed
23.
Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013;19(3):197–209.PubMedCentralPubMed
24.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedCentralPubMed
25.
Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia. 2011;13:504–15.PubMedCentralPubMed
26.
De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G. Effect of the chronic treatment with l-acetylcarnitine in Down's syndrome. Clin Ter. 1994;144(2):123–7.PubMed
27.
De Grandis D, Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 2002;3(4):223–31.PubMed
28.
De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli Jr DR, et al. l-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;39(11):1216–25.PubMed
29.
Dossus L, Kaaks R. Nutrition, metabolic factors and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008;22(4):551–71.PubMed
30.
Duffy LS, Greenberg DB, Younger J, Ferraro MG. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics. 1999;40:304–8.PubMed
31.
Dutta A, Ray K, Singh VK, Vats P, Singh SN, Singh SB. l-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp Physiol. 2008;93(10):1139–46.PubMed
32.
Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36(10):867–85.PubMedCentralPubMed
33.
Erbas H, Aydogdu N, Usta U, Erten O. Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide. Cell Biol Int. 2007;31:1414–9.PubMed
34.
Federighi G, Macchi M, Bernardi R, Scuri R, Brunelli M, Durante M, et al. Differentially expressed genes in Hirudo medicinalis ganglia after acetyl-l-carnitine treatment. PLoS One. 2013;8(1):e53605–11.PubMedCentralPubMed
35.
Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-l-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005;219(3):154–66.PubMed
36.
Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012;4(2):51–60.PubMedCentralPubMed
37.
Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of acetyl-l-carnitine: studies in vitro. J Neurosci Res. 1994;37(1):92–6.PubMed
38.
Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, et al. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat. 2004;85(1):89–97.PubMed
39.
Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, et al. Acetyl-l-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism. 2000;49(6):704–8.PubMed
40.
Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat. 2012;134(2):693–700.PubMedCentralPubMed
41.
Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10:313–25.PubMedCentralPubMed
42.
Gülçin I. Antioxidant and antiradical activities of l-carnitine. Life Sci. 2006;78(8):803–11.PubMed
43.
Gunes D, Kirkim G, Kolatan E, Guneri EA, Ozogul C, Altun Z, et al. Evaluation of the effect of acetyl l-carnitine on experimental cisplatin ototoxicity and neurotoxicity. Chemotherapy. 2011;57(3):186–94.PubMed
44.
Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, et al. Feeding acetyl-l-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99(4):1870–5.PubMedCentralPubMed
45.
Hansen MV, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, et al. The effect of melatonin on depression, anxiety, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ. 2012;2(1):e000647–55.
46.
Hayashi T. Estrogen, SERM. Nihon Rinsho. 2011;69(7):1270–4.PubMed
47.
Hoang BX, Graeme Shaw D, Pham P, Levine SA. Neuro-bioenergetic concepts in cancer prevention and treatment. Med Hypotheses. 2007;68(4):832–43.PubMed
48.
Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31(9):664–9.PubMed
49.
Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939–46.PubMed
50.
Husain S, Crosson CE. Role of PKCepsilon in PGF2alpha-stimulated MMP-2 secretion from human ciliary muscle cells. J Ocul Pharmacol Ther. 2008;24(3):268–77.PubMedCentralPubMed
51.
Jeukendrup AE, Randell R. Fat burners: nutrition supplements that increase fat metabolism. Obes Rev. 2011;12(10):841–51.PubMed
52.
Jirillo E, Altamura M, Munno I, Pellegrino NM, Sabato R, Di Fabio S, et al. Effects of acetyl-l-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol Immunotoxicol. 1991;13(1–2):135–46.PubMed
53.
Khalil RM, Darwish H, El-Ashmawy NE, El-Bahrawy HA. l-carnitine ameliorates tamoxifen-associated adverse effects in breast cancer women. Int J Cancer Res. 2013;47(2):1149–57.
54.
Khalil RM, El-Ashmawy NE, El-Bahrawy HA, Darwish H. l-carnitine supplement to tamoxifen-treated breast cancer patients: protection against cardiovascular risk. Int J Med Sci. 2013;46(2):1245–54.
55.
Khalil RM, El-Bahrawy HA, El-Ashmawy NE, Darwish H. l-carnitine decreases Her-2/neu in breast cancer patients treated with tamoxifen. IOSR-JPBS. 2013;5(2):91–8.
56.
Kumaran S, Subathra M, Balu M, Panneerselvam C. Supplementation of l-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. Exp Aging Res. 2005;31(1):55–67.PubMed
57.
Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66(4):283–92.PubMed
58.
Landree LE, Hanlon AL, Strong DW, Rumbaugh G, Miller IM, Thupari JN, et al. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. J Biol Chem. 2004;279:3817–27.PubMed
59.
Lango R, Smoleński RT, Rogowski J, Siebert J, Wujtewicz M, Słomińska EM, et al. Propionyl-l-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther. 2005;19(4):267–75.PubMed
60.
Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol. 2009;27(31):5144–52.PubMedCentralPubMed
61.
Li H, Li QD, Wang PZ, Wang MS, Cui J, Diao TY, et al. The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line. Lipids Health Dis. 2011;10:108–18.PubMedCentralPubMed
62.
Lien EA, Anker G, Ueland PM. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Biol. 1995;55(2):229–31.PubMed
63.
Macciò A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. Sci Wor J. 2011;11:2020–36.
64.
Maestri A, De Pasquale CA, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-l-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005;91:135–8.PubMed
65.
Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, et al. Effects of l-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci. 2006;51(12):2242–7.PubMed
66.
Micheletti R, Giacalone G, Bianchi G. Effect of propionyl-l-carnitine on the mechanics of right and left papillary muscles from volume-overloaded rat hearts. J Cardiovasc Pharmacol. 1996;27(1):52–7.PubMed
67.
Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J Child Neurol. 1995;10(2):S40–4.PubMed
68.
Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003;18(2):61–71.PubMed
69.
Mook D, Felger J, Graves F, Wallen K, Wilson ME. Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques. Psychoneuroendocrinology. 2005;30(3):273–83.PubMed
70.
Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137(7):1123–30.PubMed
71.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3:269–80.PubMed
72.
Naini AE, Sadeghi M, Mortazavi M, Moghadasi M, Harandi AA. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2012;23(3):484–8.PubMed
73.
Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 2007;67:1282–90.PubMed
74.
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008;68(13):1477–86.PubMedCentralPubMed
75.
Ng VL. Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med. 2009;29:253–63.PubMed
76.
Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther. 2008;83(5):702–10.PubMedCentralPubMed
77.
Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and l-carnitine. Nutrients. 2011;3(8):735–55.PubMedCentralPubMed
78.
Palva T, Ranta H, Koivisto AM, Pylkkänen L, Cuzick J, Holli K. A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo—a substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer. 2013;49(1):45–51.PubMed
79.
Porter NS, Jason LA, Boulton A, Bothne N, Coleman B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern Complement Med. 2010;16(3):235–49.PubMed
80.
Pritchard KI, Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006;66(13):1727–40.PubMed
81.
Puca FM, Genco S, Specchio LM, Brancasi B, D'Ursi R, Prudenzano A, et al. Clinical pharmacodynamics of acetyl-l-carnitine in patients with Parkinson's disease. Int J Clin Pharmacol Res. 1990;10(1–2):139–43.PubMed
82.
Puig T, Relat J, Marrero PF, Haro D, Brunet J, Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res. 2008;28(6A):3671–6.PubMed
83.
Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes CS, Illera JC. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17β-estradiol) in canine mammary tumours. J Steroid Biochem Mol Biol. 2008;110:76–82.PubMed
84.
Radhakrishnan Y, Busby Jr WH, Shen X, Maile LA, Clemmons DR. Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J Biol Chem. 2010;285(21):15682–95.PubMedCentralPubMed
85.
Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009;61(14):1332–42.PubMed
86.
Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther. 2008;7(9):2977–87.PubMed
87.
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115(4):450–8.PubMed
88.
Sener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N, et al. l-carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006;22(1):47–60.PubMed
89.
Sharma S, Neetu S, Wiseman DA, Carter L, Kumar S, Hou Y, et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;294:L46–56.PubMedCentralPubMed
90.
Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. l-carnitine and cancer cachexia: clinical and experimental aspects. J Cachexia Sarcopenia Muscle. 2011;2(1):37–44.PubMedCentralPubMed
91.
Singh B, Bhat NK, Bhat HK. Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness. PLoS One. 2011;6(9):e25125–36.PubMedCentralPubMed
92.
Spichiger E, Müller-Fröhlich C, Denhaerynck K, Stoll H, Hantikainen V, Dodd M. Prevalence of symptoms, with a focus on fatigue, and changes of symptoms over three months in outpatients receiving cancer chemotherapy. Swiss Med Wkly. 2011;141:w13303–13.PubMed
93.
Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol. 2005;6(8):581–8.PubMed
94.
Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, et al. Effects of toremifene and tamoxifen on lipid profiles in postmenopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol. 2010;40(7):627–33.PubMed
95.
Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012;106:6–13.PubMedCentralPubMed
96.
Tunstall RJ, McAinch AJ, Hargreaves M, van Loon LJ, Cameron-Smith D. Reduced plasma free fatty acid availability during exercise: effect on gene expression. Eur J Appl Physiol. 2007;99(5):485–93.PubMed
97.
98.
Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004;66(2):276–82.PubMed
99.
Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann NY Acad Sci. 2006;1083:329–44.PubMed
100.
Wenzel U, Nickel A, Daniel H. Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr. 2005;135(6):1510–4.PubMed
101.
Westlund KN, Lu Y, Werrbach-Perez K, Hulsebosch CE, Morgan B, Pizzo DP, et al. Effects of nerve growth factor and acetyl-l-carnitine arginyl amide on the human neuronal line HCN-1A. Int J Dev Neurosci. 1992;10(5):361–73.PubMed
102.
Winter S, Jue K, Prochazka J, Francis P, Hamilton W, Linn L, et al. The role of l-carnitine in pediatric cardiomyopathy. J Child Neurol. 1995;10(2):S45–51.PubMed
103.
Xu S, Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Transport of l-carnitine in human corneal and conjunctival epithelial cells. Mol Vis. 2010;16:1823–31.PubMedCentralPubMed
104.
Yamada S, Matsuda R, Nishimura F, Nakagawa I, Motoyama Y, Park YS, et al. Carnitine-induced senescence in glioblastoma cells. Exp Ther Med. 2012;4(1):21–5.PubMedCentralPubMed
105.
Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SGD, Sachdanandam P. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem. 2007;40:623–8.PubMed
106.
Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6(1):e16470–3.PubMedCentralPubMed
Metadaten
Titel
A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer
verfasst von
Nahla E. El-Ashmawy
Rania M. Khalil
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1477-5

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Research Article

The prognostic value of Smad4 mRNA in patients with prostate cancer

Research Article

Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line

Research Article

The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies

Research Article

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients

Research Article

Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis

Research Article

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise